NUCB1 and breast carcinoma: Similarly, a data-driven optimized cutpoint for Nuc-pYStat5 derived using the ScanScopeFL/TissueStudio fluorescence immunohistochemistry platform identified a similar population of tumors with low levels of Nuc-pYStat5 (19%) at a comparable 3.7-fold increased risk of breast cancer recurrence (hazard ratio 3.69 (1.57–8.65), P=0.003, N=193; Figure 2c).